Conference Proceedings
ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY
Karl Lewis, Paolo Ascierto, Caroline Robert, Rodrigo Munhoz, Gabriella Liszkay, Luis De La Cruz Marino, Judit Olah, Paola Queirolo, Jacek Mackiewicz, Kalpit Shah, Harper Forbes, Christian Hertig, Yibing Yan, Ralf Gutzmer, Grant McArthur
JOURNAL FOR IMMUNOTHERAPY OF CANCER | BMJ PUBLISHING GROUP | Published : 2020
Abstract
The phase 3 IMspire150 study (NCT02908672) showed that first-line atezolizumab (A) combined with vemurafenib (V) + cobimetinib (C) improved progression-free survival (PFS) vs placebo (P) + V + C in patients with BRAFV600 mutation–positive advanced melanoma (15.1 vs 10.6 months; hazard ratio [HR] 0.78; 95% CI 0.63–0.97; P=0.0249). Insights into the clinical benefit of the A+V+C triple combination in prognostic molecular subgroups of patients can inform treatment selection and future clinical research. 514 patients were randomized 1:1 to A+V+C (n=256) or P+V+C (n=258). The efficacy endpoints analyzed included PFS and duration of response (DOR) estimated using the Kaplan-Meier method. Outcomes ..
View full abstract